Influx Healthtech IPO: Price, Overview, And GMP

Influx Healthtech IPO- Complete Overview

Influx Healthtech IPO under the SME IPO category is a book build issue of Rs. 58.57 Cr by Influx Healthtech Limited. The company was established in 2020 and is a healthcare company with a focus on the modern health system. The company is a trusted long-term partner in CDMO services to clients in a number of important industries.

The company operates three manufacturing units in Thane, Maharashtra, which are 9,676 square feet, 13,000 square feet, and 14,000 sq ft, respectively.

Product Portfolio

• Tablets, capsules and powders.

• Liquid orals and softgels.

• Wafers, jellies, and gummies.

• Oral Dispersible Films (ODFs).

• Water-soluble tablets & liquid-filled capsules.

• Candy and gym/sports supplements.

• Skin and body care products.

• This is hair care and beard care.

• Face masks and soaps.

• Ayurvedic / herbal compositions.

• Veterinary feed supplements.

• Homecare solutions.

The Company supports Nutraceutical and Cosmetic companies in product development and production. It provides vertically integrated services from development through commercialization, including formulation, analytical testing, clinical-trial materials and packaging of drugs and devices for the pharmaceutical and medical device industries. 

 

 

Influx Healthtech IPO Overview

The Influx Healthtech IPO date is on 18 June 2025, and its initial public offering will end on 20 June 2025. 

The Rs. 58.57 crore new SME IPO comprises a combination of a fresh issue of 50 lac Shares (Rs. 48 Cr) and an offer for sale (OFS) of 11 lac Shares (Rs. 10.56 Cr). 

This upcoming IPO is available for subscription from June 18 to 20 June 2025. Influx Healthtech IPO price is Rs. 91 to Rs. 96 for each Share. 

The expected Influx Healthtech IPO listing date is Jun 25, 2025, and listing at the NSE and SME.

Click to open demat account and apply for the IPO.

Company Financial

(Amount in Lac)

Period	31 Mar 2025	31 Mar 2024	31 Mar 2023
Total Assets	70.30	41.10	28.30
Total Revenue	104.99	100.10	76.07
PAT	13.37	11.22	7.20
Net Worth	36.15	22.87	11.65
Reserves & Surplus	18	22.85	11.63
Borrowings	0.22	0.32	0.80

 

Cash Flows

(Amount in lac)

Net Cash Flow in Multiple Activities	31 Mar 2025	31 Mar 2024	31 Mar 2023
Net Cash Flow Operating Activities	705.62	894.25	682.24
Net Cash Flow Investing Activities	(864.47)	(835.73)	(487.96)
Net Cash Flow Financing Activities	(10.66)	(52.67)	13.91

 

Revenue Bifurcation

Project-wise Revenue Bifurcation

 

Segment-wise Revenue Bifurcation

(Source: RHP)

 

The Objective of the Issue

The company desires to use the Net Proceeds from the Issue to fulfill its following goals:

• Financing the necessary capital expenditures to establish a manufacturing facility for the Nutraceutical Division.

• Capital expenditure is needed for funding the establishment of the Veterinary Food Division's manufacturing facility.

• Acquisition of equipment for the cosmetics and homecare sector.

• General corporate purposes.
  
  

Click to check the IPO application status.

Peers of Influx Healthtech Ltd.

Company Name	Face Value (Rs.)	EPS (Rs.)	P/E (x)
Sudarshan Pharma Industries Ltd.	1	0.66	48.28
Quest Laboratories Limited	10	8.28	10.38

 

 

Evaluation

The Influx Healthtech Limited IPO price is Rs. 91 to Rs. 96 for each Share.

Evaluation of P/E Ratio

Considering the FY ended 31 Mar 2025 with an EPS of Rs. 7.36 from the last year, the resulting P/E ratio is 13.04x.

Considering the weighted EPS of Rs. 6.39 for the last three years, the P/E ratio is 15.02x.

Explore Patil Automation IPO.

 

Comparative Analysis With Listed Peers

The average P/E Ratio of the industry is 29.33.

Particulars	P/E Ratio (x)
Highest	48.28
Lowest	10.38
Average	29.33

In simple words, the P/E ratio of this IPO (13.04x), compared with the industry’s average P/E of 29.33x, has an undervaluation (on a P/E ratio basis only). Hence, the price of the Share seems fairly priced for the investors when considered based on the average P/E ratio of the industry.

 

IPO's Strengths

• The spectrum of products comes with diversification.

• The nature of the clientele is varied.

• Tough QA/QC checks are undertaken.

• Experienced and qualified promoters and management team.

 

IPO’s Weaknesses

• The company has significant exposure to the nutraceuticals category. Any slowing down or shift in business, in these sectors such as clients making their products, could result in reduced demand for the company’s services and could negatively impact its revenue and business.

• It's using trademarks and domain names to defend this competitive advantage. In light of these restrictions for the unlicensed use or insufficient safeguarding of these proprietary rights, it could result in legal action, loss of income, and harm to the brand and business operations.

• The company depends heavily on independent distributors and logistics firms to operate. When the response of these supply chain partners becomes sensitive to irritants such as disturbances, inefficiencies, or low quality in service, it could damage the business performance as a whole.  

 

Influx Healthtech IPO GMP

Influx Healthtech IPO GMP is Rs. 40 as of 17 Jun 2025 while writing this information. Hence, its estimated listing price is Rs. 136.

IPO Timetable (Tentative)

The Influx IPO date of opening is from Jun 18 to Jun 20, 2025, allotment on Jun 23, refund initiation on Jun 24, and listing on Jun 25, 2025.

Events	Date
IPO Opening Date	Jun 18, 2025
IPO Closing Date	Jun 20, 2025
IPO Allotment Date	Jun 23, 2025
Refund Initiation	Jun 24, 2025
IPO Listing Date	Jun 25, 2025

 

Influx Healthtech IPO Details 

The IPO with a Face Value of Rs. 10 per share offers a total issue size of 61,00,800 Shares (Rs. 58.57 Cr).

IPO Opening & Closing date	18 Jun, 2025 to 20 Jun, 2025
Face Value	Rs. 10 per Share
Issue Price	Rs. 91 to Rs. 96 per Share.
Lot Size	1200 Shares
Issue Size	61,00,800 Shares (Rs. 58.57 Cr)
Offer for Sale	11,00,400 Shares (Rs. 10.56 Cr)
Fresh Issue	50,00,400 Shares (Rs. 48 Cr)
Listing at	NSE, SME
Issue Type	Book building Issue
Registrar	Maashitla Securities Private Limited

 

 

IPO Lot Details 

The IPO allows retail investors to invest in a minimum and maximum of 1 Lot (1200 Shares) amounting to Rs. 1,15,200 and in multiples thereof, while for HNI investors, the minimum Lot is 2 (2400 Shares) amounting to Rs. 2,30,400.

Minimum Lot Investment (Retail)	1 Lot
Maximum Lot Investment (Retail)	1 Lot
HNI (Min)	2 Lots

 

IPO Reservation (% of Net Issue)

Institutional’s Portion	50%
Retail’s Portion	35%
Non-Institutional’s Portion	15%

 

Promoters And Management of Influx Healthtech Ltd.

• Mr. Munir Abdul Ganee Chandniwala

• Mrs. Shirin Munir Ahmed Chandniwala

• Mr. Abdul Ganee Abdul Rasul Chandniwala.

Pre-Issue Promoter Shareholding	99.85%
Post-Issue Promoter Shareholding	73.53%

 

IPO Lead Managers

• Rarever Financial Advisors Pvt. Ltd.

 

 

Dividend Policy

The company hasn’t paid a dividend in any year. 

 

Conclusion

Influx Healthtech IPO is an opportunity to bet on a fast-growing healthcare and nutraceutical company with a diversified product portfolio. At a fairly priced IPO, strong financial growth and experienced promoters should attract investors. But prospective investors should first weigh related sector and operational risks prior to applying. 

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is for educational and information purposes only. Always discuss with your eligible financial advisor for investment-related decisions. 

 

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO. 

You must consult your financial advisor before making any financial decisions. 

To Apply for the IPO, Click Here.

To Read the Prospectus of the Company Click Here to Download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.